secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001193125-26-186939
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health Q1 revenue falls to $124.2M, net loss narrows; pipeline advances
----------------------------------------------------------------------------

- Consolidated revenue $124.2M vs $149.9M YoY; net loss $54.8M ($0.07/sh) from $67.6M ($0.10/sh).
- Pharma revenue $38.0M (+9% YoY); Diagnostics $72.2M, down from $102.8M due to Labcorp oncology asset sale.
- Operating loss improved to $51.0M from $67.2M; cash $341.9M; $92M of stock repurchased under $200M authorization.
- Phase 1 trials started for MDX2301 (COVID-19 prevention) and MDX2003 (B-cell lymphoma); in vivo CAR-T platform advancing.
- FY2026 guidance reaffirmed: total revenue $530-560M; total costs $725-750M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000119312526186939/0001193125-26-186939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000119312526186939/opk-20260428.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-186939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer